Initial Anti-Biofilm Lab Results Suggest Ash Access Technology, Inc.'s Emerging Heparin-Replacement Catheter Lock Has Even Greater Infection-Prevention Attributes


LAFAYETTE, Ind. -- Ash Access Technology, Inc. revealed more laboratory results today, adding anti-biofilm characteristics to previously reported antimicrobial results, thereby further strengthening MethLock's position as a serious contender to replace heparin in a $1 billion market.


"We plan to perform more rigorous tests, similar to the extensive tests we did to verify MethLock's antimicrobial attributes, but we are pleased with these first results," explains Roland K. Winger, vice president of engineering and quality assurance.  "Since biofilm creates a friendly environment to host harmful bacteria associated with catheter-related

bloodstream infections (CRBSI), a key objective was to prevent biofilm growth. MethLock's anti-biofilm attributes help us understand its great potential for prevention of costly and deadly infection." 


"These results just add to our growing excitement about the impact we expect MethLock to make toward saving lives threatened by catheter-related bloodstream infections," says Robert B. Truitt, president and CEO of Ash Access Technology, Inc.  "By preventing biofilm buildup in catheters, and removing bacteria's favorite colonization grounds, we would expect to see a dramatic reduction in the billions of dollars estimated to be lost to these infections every year, (once our clinical trial is complete and we go to

market with MethLock in dialysis, oncology, and other chronic and acute



Ash Access Technology, Inc. is a privately held company founded to develop

antimicrobial and vascular access technologies, devices and methodologies to

combat the deadly and expensive problem of catheter-related bloodstream

infections (with an emphasis on prevention). 


Source: Ash Access Technology, Inc.

Related Videos
An eye instrument holding an intraocular lens for cataract surgery. How to clean and sterilize it appropriately?   (Adobe Stock 417326809By Mohammed)
UV-C Robots by OhmniLabs.  (Photo from OhmniLabs website.)
CDC  (Adobe Stock, unknown)
Laparoscopy(Adobe Stock 338216574 by Damian)
Sterile processing   (Adobe Stock, unknown)
Jill Holdsworth, CIC, FAPIC, NREMT, CRCST, manager of infection prevention at Emory University Hospital Midtown; and Cheron Rojo, BS, FCs, CHL, CIS, CER, CFER, CRCST, clinical education coordinator for sterile processing departments, Healthmark
The Joint Commission Seal
Jill Holdsworth and Adam Lorentz discussing urology and infection control
Related Content